Dyadic International, Inc. (AMEX: DIL), a biotechnology company, announced today that it has hired Charles W. (Bill) Kling IV as Vice President, Sales & Marketing, Enzymes. In addition to Mr. Kling, Dyadic also hired four additional technical sales representatives to support the company's global effort in pulp and paper.

Mr. Kling will head up Dyadic's Enzyme Business sales and marketing efforts with particular focus on pulp and paper, and will report to Kent Sproat, Executive Vice President, Enzymes. Mr. Kling is a veteran of the pulp and paper industry, where he has successfully introduced a number of new products during his 27-year career. He joins Dyadic directly from Hercules, Inc., where he was Group Manager of the Pulp and Paper division and was responsible for a staff of over 60 people. From 1990 to 1998 he served as Global Director, Technical Marketing, at BetzDearborn, Inc.'s Pulp and Paper division. Prior to that he was employed by Scott Paper and Buckeye Cellulose, a division of Proctor and Gamble, Inc.

Dyadic estimates the addressable market for its existing enzyme products in the pulp and paper industry and potential enzyme products for the pulp and paper industry currently in its research and development pipeline to be in excess of $1.0 billion. Currently, the company's enzymes are undergoing trials in a number of paper companies throughout the world. The trials seek to evaluate the economic impact Dyadic's products have on the bleach-boosting, bio-refining and de-inking processes. Some of these potential improvements include significant cost-savings in the use of chemicals and energy, improvements in paper quality, and reduction in effluent streams.

"The addition of Bill Kling and the new sales personnel comes on the heels of our recent hiring of Dr. Dan Michalopoulos as Vice President, Pulp and Paper division. This further demonstrates our commitment to expand into the pulp and paper industry around the world," commented Mark Emalfarb, Dyadic's Chief Executive Officer. "As we continue to execute our pulp and paper business plan, we also continue to seek other large, proprietary opportunities, where our products and technologies can serve as a key element in our customers' processes or product flow."

About Dyadic
Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp and paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products.

Cautionary Statement for Forward-Looking Statements
Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to our business. For a discussion of the factors that could cause actual results to vary from these forward-looking statements, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, which was filed with the SEC on April 15, 2005, and our Quarterly Report for the quarter ended March 31, 2005 on Form 10-QSB, which was filed on May 17, 2005. We expressly disclaim any intent or obligation to update any forward-looking statements.